Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip

Trial Profile

Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Fasinumab (Primary) ; Celecoxib; Diclofenac
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT OA2
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 04 Sep 2018 Planned number of patients changed from 2700 to 1620.
    • 10 Jul 2018 This trial has been discontinued in Denmark.
    • 12 Mar 2018 Planned End Date changed from 5 Jun 2020 to 15 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top